शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEGODAVARI DRUGS LTD.· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 14 Aug, 2026 · 13:05 IST

Promoters convert 7.87 lakh warrants into equity shares

Warrants convertedFund Raising View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+5.0%Reaction day
₹100.00
prior close
₹98.10
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+4.9% vs market
Pharmaceuticals peers, median of 166sector-0.4%+5.4% vs sector

On the reaction day the stock moved 4.9 pts more than Nifty Microcap 250 and 5.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
+7.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+5.0+0.1+4.9-0.4+5.4
Next day
+4.0+0.2+3.8-0.5+4.4
2d
+2.0+0.6+1.4-0.6+2.6
3d
+1.0-0.0+1.0-1.4+2.4
4d
+0.0+0.5-0.5-0.9+0.9
5d
+1.0+0.8+0.2-0.4+1.4
1w
+0.0+0.6-0.6-0.9+0.9
15d
+5.5+1.3+4.2+0.0+5.5
1m
+8.0-1.4+9.4-0.1+8.1
2m
+34.5-0.6+35.0-2.8+37.2
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Godavari Drugs board on 14 Aug 2026 approved allotment of 7,86,690 equity shares to promoter group on conversion of warrants at Rs. 89 per share (Rs. 10 premium). Company received Rs. 5.25 crore as remaining 75 percent payment. Paid-up capital rose from Rs. 10.13 crore to Rs. 10.91 crore, with share count going from 1.01 crore to 1.09 crore. About 15.73 lakh warrants still pending conversion. Allottees are members of the Jaju and Kakani families.

Likely market impact

Promoter group holding increases; minor dilution for existing shareholders. Short-term EPS may dip slightly due to higher share count.